Medical Care Technologies Inc. (OTC Pink:MDCE) Advances Beyond Original AI Vision Patent - Technology Has Evolved Faster Than Expected

Rhea-AI Summary

Medical Care Technologies (OTC Pink:MDCE) announced it will not proceed with U.S. Provisional Patent Application No. 63/854,935 for its AI vision technology, as internal innovation has surpassed the original filing.

The company highlights newer proprietary AI vision systems now used in Vision API services, the MDCE Melanoma Scan Beta platform, and image-recognition features within Snapshot Recipes and RealGameUsed.com authentication workflows, emphasizing a shift toward rapid commercialization and future intellectual property based on its latest advances.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Rapid Internal Innovation Renders U.S. Provisional Patent Application No. 63/854,935 Obsolete, Highlighting Exceptional Velocity in AI Development

MESA, AZ / ACCESS Newswire / July 2, 2026 / Medical Care Technologies Inc. (OTC PINK:MDCE) today announced that it has elected not to proceed with its U.S. Provisional Patent Application No. 63/854,935, originally filed in July 2025 for its AI Vision Technology. This decision reflects the Company's accelerated pace of innovation, as its current proprietary AI vision systems and software have advanced significantly beyond the original application.

Since filing the provisional patent in July 2025, MDCE's engineering teams have achieved substantial breakthroughs in computer vision algorithms, real-time image processing, model efficiency, and practical deployment across multiple platforms. These advancements have made the 2025 provisional application outdated, as the Company's live and beta technologies now deliver superior performance and capabilities.

"Our AI vision technology and software development has progressed at a speed that surpassed even our own expectations," said Marshall Perkins, CEO of Medical Care Technologies. "Instead of pursuing an application that no longer reflects our current state-of-the-art systems, we are fully focused on deploying and protecting our next-generation solutions that are already powering real-world products and delivering strong results. This demonstrates our agility and commitment to staying far ahead of the curve."

Key current implementations of MDCE's evolved AI Vision technology include:

• Vision API Services now available through the corporate website for enterprise clients

• MDCE Melanoma Scan Beta platform, showing promising internal testing results

• Advanced image recognition features integrated into Snapshot Recipes and RealGameUsed.com authentication workflows

This strategic decision underscores MDCE's dynamic development culture and focus on rapid commercialization of cutting-edge solutions rather than legacy filings. The Company continues to evaluate new intellectual property opportunities based on its latest innovations across AI imaging, digital wellness, and authentication technologies.

About Medical Care Technologies, Inc.

Medical Care Technologies, Inc. (OTC PINK:MDCE) is a technology company focused on artificial intelligence, imaging technologies, digital wellness platforms, authentication technologies, and advanced software development initiatives. The Company is actively developing AI-assisted imaging and computer vision technologies designed to support emerging opportunities across digital health, preventative wellness, and consumer applications.

Contact Information
Medical Care Technologies, Inc.
Website: https://medicalcaretechnologies.com/
Email: info@medicalcaretechnologies.com
Phone: 1-480-645-0750
Address: 1910 S. Stapley Drive, Suite 221, Mesa, AZ 85204

Safe Harbor Statement This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding product development, intellectual property strategy, future platform capabilities, and business strategy. Actual results may differ materially from those projected. Medical Care Technologies undertakes no obligation to update forward-looking statements except as required by law.

SOURCE: Medical Care Technologies Inc.

View the original press release on ACCESS Newswire

FAQ

What did Medical Care Technologies (OTC Pink:MDCE) announce on July 2, 2026?

Medical Care Technologies announced it will not advance U.S. Provisional Patent Application No. 63/854,935. According to Medical Care Technologies, its AI vision technology has evolved far beyond the 2025 filing, making current proprietary systems more relevant for protection and commercialization.

Why is MDCE discontinuing its original AI vision provisional patent application 63/854,935?

MDCE is discontinuing the 63/854,935 provisional because it no longer reflects its current AI vision systems. According to Medical Care Technologies, breakthroughs in algorithms, real-time processing, and deployment have rendered the 2025 application outdated versus today’s live and beta technologies.

How is Medical Care Technologies’ evolved AI vision technology currently being used?

MDCE’s evolved AI vision powers Vision API services, a Melanoma Scan Beta platform, and image recognition in Snapshot Recipes and RealGameUsed.com. According to Medical Care Technologies, these implementations support enterprise clients, digital wellness use cases, and authentication workflows across multiple platforms.

What is the MDCE Melanoma Scan Beta platform and its current status?

The MDCE Melanoma Scan Beta is a digital wellness platform using the company’s AI vision for melanoma-related imaging. According to Medical Care Technologies, it is in beta with promising internal testing results, supporting the firm’s broader AI imaging and healthcare-focused initiatives.

How can enterprise clients access MDCE’s Vision API services for AI imaging?

Enterprise clients can access MDCE’s Vision API services through the company’s corporate website. According to Medical Care Technologies, these services expose its proprietary AI vision capabilities for real-time image processing and recognition, supporting deployment across multiple platforms and commercial use cases.

What does MDCE’s AI patent decision mean for future intellectual property strategy?

The decision signals a focus on protecting newer AI vision innovations rather than an outdated 2025 filing. According to Medical Care Technologies, the company will keep evaluating fresh intellectual property opportunities across AI imaging, digital wellness, and authentication technologies as its systems advance.